Overview

A Study for Participants With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
This drug is being evaluated for possible treatment of type 2 diabetes mellitus. Participation in this study is expected to last up to 18 weeks. A goal of this study is to determine the safety and effectiveness of LY2409021.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company